.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Chinese Patent Office
Fish and Richardson
Healthtrust
Merck
Accenture
McKesson
US Army
Teva
Dow

Generated: December 17, 2017

DrugPatentWatch Database Preview

Gilead Sciences Inc Company Profile

« Back to Dashboard

What is the competitive landscape for GILEAD SCIENCES INC, and when can generic versions of GILEAD SCIENCES INC drugs launch?

GILEAD SCIENCES INC has sixteen approved drugs.

There are sixty US patents protecting GILEAD SCIENCES INC drugs and there have been two Paragraph IV challenges on GILEAD SCIENCES INC drugs in the past three years.

There are one thousand four hundred and nineteen patent family members on GILEAD SCIENCES INC drugs in sixty-five countries and one hundred and sixty-two supplementary protection certificates in fifteen countries.

Summary for Gilead Sciences Inc

International Patents:1419
US Patents:60
Tradenames:15
Ingredients:15
NDAs:16
Drug Master File Entries: 7
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead Sciences IncVIREADtenofovir disoproxil fumarateTABLET;ORAL021356-004Jan 18, 2012RXYesNo► Subscribe► SubscribeY► Subscribe
Gilead Sciences IncSOVALDIsofosbuvirTABLET;ORAL204671-001Dec 6, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Gilead Sciences IncVITEKTAelvitegravirTABLET;ORAL203093-001Sep 24, 2014DISCNYesNo► Subscribe► SubscribeYY► Subscribe
Gilead Sciences IncGENVOYAcobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarateTABLET;ORAL207561-001Nov 5, 2015RXYesYes► Subscribe► SubscribeYY► Subscribe
Gilead Sciences IncGENVOYAcobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarateTABLET;ORAL207561-001Nov 5, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Gilead Sciences IncVOSEVIsofosbuvir; velpatasvir; voxilaprevirTABLET;ORAL209195-001Jul 18, 2017RXYesYes► Subscribe► SubscribeYY► Subscribe
Gilead Sciences IncVIREADtenofovir disoproxil fumarateTABLET;ORAL021356-002Jan 18, 2012RXYesNo► Subscribe► Subscribe► Subscribe
Gilead Sciences IncODEFSEYemtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarateTABLET;ORAL208351-001Mar 1, 2016RXYesYes► Subscribe► SubscribeYY► Subscribe
Gilead Sciences IncEPCLUSAsofosbuvir; velpatasvirTABLET;ORAL208341-001Jun 28, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Gilead Sciences IncHARVONIledipasvir; sofosbuvirTABLET;ORAL205834-001Oct 10, 2014RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Gilead Sciences Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gilead Sciences IncVISTIDEcidofovirINJECTABLE;INJECTION020638-001Jun 26, 1996► Subscribe► Subscribe
Gilead Sciences IncODEFSEYemtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarateTABLET;ORAL208351-001Mar 1, 2016► Subscribe► Subscribe
Gilead Sciences IncVIREADtenofovir disoproxil fumarateTABLET;ORAL021356-001Oct 26, 2001► Subscribe► Subscribe
Gilead Sciences IncVIREADtenofovir disoproxil fumarateTABLET;ORAL021356-001Oct 26, 2001► Subscribe► Subscribe
Gilead Sciences IncGENVOYAcobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarateTABLET;ORAL207561-001Nov 5, 2015► Subscribe► Subscribe
Gilead Sciences IncSTRIBILDcobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarateTABLET;ORAL203100-001Aug 27, 2012► Subscribe► Subscribe
Gilead Sciences IncDESCOVYemtricitabine; tenofovir alafenamide fumarateTABLET;ORAL208215-001Apr 4, 2016► Subscribe► Subscribe
Gilead Sciences IncCOMPLERAemtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarateTABLET;ORAL202123-001Aug 10, 2011► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for GILEAD SCIENCES INC drugs

Drugname Dosage Strength Tradename Submissiondate
cobicistatTablets150 mgTYBOST12/9/2015
emtricitabine, rilpivirine, and tenofovir disoproxil fumarateTablets200 mg/25 mg/300 mgCOMPLERA5/20/2015
tenofovir disoproxil fumarateTablets150 mg, 200 mg, and 250 mgVIREAD5/17/2012
tenofovir disoproxil fumarateTablets300 mgVIREAD1/26/2010

Non-Orange Book Patents for Gilead Sciences Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,160,999Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers► Subscribe
6,931,679 Foldable stand for a hammock► Subscribe
5,814,639 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds► Subscribe
7,468,436Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers► Subscribe
9,156,823Antiviral compounds► Subscribe
8,088,770Modulators of pharmacokinetic properties of therapeutics► Subscribe
6,346,627 Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers► Subscribe
8,067,449Modulators of pharmacokinetic properties of therapeutics► Subscribe
8,859,756Stereoselective synthesis of phosphorus containing actives► Subscribe
8,383,655Modulators of pharmacokinetic properties of therapeutics► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Gilead Sciences Inc Drugs

Country Document Number Estimated Expiration
Slovenia2552930► Subscribe
South Korea100188357► Subscribe
Lithuania2432792► Subscribe
Japan2014528924► Subscribe
Luxembourg92001► Subscribe
European Patent Office1789139► Subscribe
Hong Kong1213572► Subscribe
LithuaniaPA2016042► Subscribe
World Intellectual Property Organization (WIPO)9804569► Subscribe
Argentina036387► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Gilead Sciences Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016042Lithuania► SubscribePRODUCT NAME: RILPIVIRINO HIDROCHLORIDAS + EMTRICITABINAS + TENOFOVIRO ALAFENAMIDAS; REGISTRATION NO/DATE: EU/1/16/1112 20160621
0915894/02Switzerland► SubscribePRODUCT NAME: TENOFOVIRDISOPROXIL + EFAVIRENZ + EMTRICITABIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 60011 20.11.2009
307Luxembourg► SubscribePRODUCT NAME: ELVIEGRAVIR SOUS TOUTES SES FORMES COMME PROTEGEES PAR LE BREVET DE BASE
4 5022-2015Slovakia► SubscribePRODUCT NAME: RILPIVIRINHYDROCHLORID/TENOFOVIRDIZOPROXILFUMARAT; REGISTRATION NO/DATE: EU/1/11/737/001 - EU/1/11/737/002 20111128
2016000110Germany► SubscribePRODUCT NAME: KOMBINATION VON RILPIVIRINHYDROCHLORID ODER EINER THERAPEUTISCH AEQUIVALENTEN, DURCH DAS GRUNDPATENT GESCHUETZTEN FORM DAVON UND TENOFOVIRALAFENAMID ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/16/1112 20160621
0796Netherlands► SubscribePRODUCT NAME: LEDIPASVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/14/958 20141118
2015040Lithuania► SubscribePRODUCT NAME: COBICISTATUM; REGISTRATION NO/DATE: EU/1/13/830/001 - 002 20130524
2 6-2015Slovakia► SubscribePRODUCT NAME: EMTRICITABIN/RILPIVIRINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/737/001 - EU/1/11/737/002 20111128
0150040 00167Estonia► SubscribePRODUCT NAME: RILPIVIRIINI (VESINIKKLORIIDSOOLANA), TENOFOVIIR-;REG NO/DATE: EU/1/11/737/001-002 28.11.2011
/2014Austria► SubscribePRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894 20140117
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
QuintilesIMS
Julphar
Daiichi Sankyo
Teva
UBS
US Department of Justice
Medtronic
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot